Novo Nordisk A/S (BVMF:N1VO34)
| Market Cap | 1.04T -8.8% |
| Revenue (ttm) | 262.62B +5.7% |
| Net Income | 89.08B +9.1% |
| EPS | 2.71 +9.2% |
| Shares Out | n/a |
| PE Ratio | 10.80 |
| Forward PE | 12.16 |
| Dividend | 0.77 (2.63%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 12,498 |
| Open | 29.53 |
| Previous Close | 29.92 |
| Day's Range | 29.03 - 29.77 |
| 52-Week Range | 22.90 - 42.43 |
| Beta | 0.37 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk put volume heavy and directionally bearish
Bearish flow noted in Novo Nordisk (NVO) with 41,430 puts trading, or 4x expected. Most active are Dec-26 35 puts and Dec-27 40 puts, with total volume in those strikes…
Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?
Lilly's revenue growth is turbocharged by its weight-loss pipeline, while Novo's global footprint and far lower valuation raise a tougher question about risk versus reward.
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue
Johnson & Johnson's revenue has climbed quarter after quarter, while Novo Nordisk's has stayed largely flat apart from one notable jump.
Novo Nordisk presents new research that includes cagrilintide study
The company states: “Novo Nordisk (NVO) presented new research at ObesityWeek 2026 exploring biomarkers related to bone health across multiple investigational amylin-based medicines in its weight loss...
Novo's Wegovy cuts BMI by 17.4% in obese children aged 6 to 11 in late-stage trial
Novo Nordisk's Wegovy cut BMI by 17.4% over 68 weeks in children aged 6 to 11 with obesity, according to full late-stage trial results reported by CNBC.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo released full results from a late-stage trial showing Wegovy helped children ages 6 to under 12 with obesity significantly lower their body mass index. Wegovy is already approved to treat obesity...
New research shows weight-loss drugs could be an effective option for children as young as 6 years old
Novo Nordisk's study of GLP-1s in children as young as 6 years old worked for shedding pounds but raised questions about growth rates.
Novo Nordisk Shares Rise on Positive Weight-Loss Data, Hemophilia Drug Approval
The Danish drugmaker released encouraging results from studies and European regulators approved a hemophilia treatment, pushing the stock higher premarket.
Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027
Eli Lilly is surging, with revenue up 39% in the third quarter and a retatrutide filing planned for early 2027. Novo is bouncing back on oral Wegovy, with a CagriSema decision due soon.
Novo Nordisk announces results from two post hoc analyses of phase 3 Redefine 1
Novo Nordisk (NVO) announced results from two post hoc analyses of the phase 3 Redefine 1 trial of investigational CagriSema 2.4 mg / 2.4 mg, a fixed-dose combination of the…
Novo Nordisk presents findings on reduction in food noise when using Wegovy
Novo Nordisk (NVO) presented real-world findings from the Signal and Octane studies at ObesityWeek 2026, looking at how food noise scores changed for adults with overweight or obesity taking Wegovy…
Novo Nordisk announces primary results from Phase 3 Redefine 9 trial
Novo Nordisk (NVO) announced primary results from the phase 3 Redefine 9 trial of investigational CagriSema, a fixed-dose combination of the long-acting amylin analog cagrilintide and the GLP-1 recept...
Novo Nordisk Says Wegovy May Help Reduce 'Food Noise' In Adults With Obesity
(RTTNews) - Novo Nordisk (NVO) presented new real-world data at ObesityWeek 2026 suggesting that Wegovy (semaglutide) may help reduce "food noise," an emerging obesity-care concept describing persiste...
Novo Nordisk Reports Strong Weight-Loss Results In Phase 3 REDEFINE 9 Trial Of CagriSema
(RTTNews) - Novo Nordisk (NVO) announced positive primary results from the Phase 3 REDEFINE 9 trial evaluating CagriSema, an investigational treatment for adults with overweight or obesity. CagriSema ...
Weight-loss pill helps patients lose 6% of body weight in three months: data
Patients who stayed on Novo Nordisk’s daily Wegovy pill lost an average of 6.2 per cent of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conf...
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?
Novo Nordisk A/S maintains a leading position in the high-growth obesity and diabetes treatment markets. Pfizer offers a highly diversified product portfolio and significant free cash flow generation.
Novo Nordisk Secures EU Approval For FREHEMGO In Haemophilia A
(RTTNews) - Novo Nordisk (NVO, NOVOB.CO, NOV.DE) has received European Commission marketing authorization for FREHEMGO (denecimig), a next-generation therapy for the routine prophylaxis of bleeding ep...
Novo's haemophilia drug gets EU approval
Novo Nordisk said on Friday the European Commission has granted approval for its treatment to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A, a rare blo...
Novo Nordisk submits etavopivat NDA to FDA, etavopivat MAA to EMA
Novo Nordisk (NVO) announced the submissions of a new drug application, or NDA, to the FDA and a marketing authorization application, or MAA, to the European Medicines Agency, or EMA,…
Novo Nordisk says Wegovy pill to cost up to $395 per month
The Danish drugmaker has announced the recommended pricing for its Wegovy tablet that is expected to go on sale in Australia by the end of the year.
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the cou...
Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
DJ Khaled has been losing weight with Wegovy® (semaglutide) injection for a year and is eager to keep going and put in the work Khaled will share his experience and invite fans to follow his progress ...
JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?
Novo Nordisk lived up to expectations for its Wegovy pill in the third quarter, but it still has more work ahead.
Novo Nordisk Commits $200 Million To Expand Diabetes Prevention And Care In Developing
(RTTNews) - Novo Nordisk (NVO) has pledged $200 million over the next 10 years to support the World Diabetes Foundation (WDF) in expanding diabetes prevention and care programs across low-and middle-i...